<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem. Biol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Chemical Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem. Biol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2813-530X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1736812</article-id>
<article-id pub-id-type="doi">10.3389/fchbi.2026.1736812</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Redox potential fine tuning of ferrocene-peptide conjugates</article-title>
<alt-title alt-title-type="left-running-head">Difino et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchbi.2026.1736812">10.3389/fchbi.2026.1736812</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Difino</surname>
<given-names>Alessia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Biondi</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1730338"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bisello</surname>
<given-names>Annalisa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cardena</surname>
<given-names>Roberta</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing &#x2013; review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lastella</surname>
<given-names>Luana</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing &#x2013; review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>&#x160;imi&#x107;</surname>
<given-names>Marko</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calderaro</surname>
<given-names>Beatrice</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Formaggio</surname>
<given-names>Fernando</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/612240"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rancan</surname>
<given-names>Marzio</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Santi</surname>
<given-names>Saverio</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3260938"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing &#x2013; review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Chemistry, University of Padova</institution>, <city>Padova</city>, <country country="IT">Italy</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Institute of Biomolecular Chemistry, Padova Unit, National Research Council (CNR)</institution>, <city>Padova</city>, <country country="IT">Italy</country>
</aff>
<aff id="aff3">
<label>3</label>
<institution>Institute of Condensed Matter Chemistry and Technologies for Energy (ICMATE), National Research Council (CNR)</institution>, <city>Padova</city>, <country country="IT">Italy</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Saverio Santi, <email xlink:href="mailto:saverio.santi@unipd.it">saverio.santi@unipd.it</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-30">
<day>30</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>5</volume>
<elocation-id>1736812</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Difino, Biondi, Bisello, Cardena, Lastella, &#x160;imi&#x107;, Calderaro, Formaggio, Rancan and Santi.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Difino, Biondi, Bisello, Cardena, Lastella, &#x160;imi&#x107;, Calderaro, Formaggio, Rancan and Santi</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-30">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>We report the synthesis of new ferrocene (Fc)-peptide conjugates, namely, N-Fc-succinamide-Gly-Ala-OEt, N-Fc-glutaramide-Gly-Ala-OEt, N-Fc-pimelamide-Gly-Ala-OEt, and N-Fc-glutaramide-Gly-Gly-Ala-OEt. They were designed on the base of four components: (i) a Fc unit as an electroactive element; (ii) the linker -NH-CO- to adjust the oxidation potential of Fc towards the physiological conditions; (iii) spacers of different lengths between Fc and the peptide; (iv) a peptide unit to drive Fc to selected biological targets. Fc-peptide conjugates have already been explored as potential anticancer drugs. It is reported that Fc displays the anti-proliferative activity through the production of reactive oxygen species (ROS) as its redox potential (0.40&#xa0;V vs. SCE) is compatible with the intracellular potential which varies from &#x2b;0.40&#xa0;V to &#x2212;0.44&#xa0;V. However, the way Fc binds to the peptide significantly influences its redox potential. So far, this issue was not deeply addressed in the literature. Therefore, in this contribution we aimed at investigating the influence of the linker, and of the length of spacer and peptide on the Fc oxidation potential. Noteworthy, we linked Fc to the remaining part of the molecule via an amide bond, but with N-end attached to Fc and not the carbonyl, as reported in the literature so far. The cyclic voltammetry measurements we performed revealed that the transition from an electron-withdrawing (Fc-CO-NH-) to an electron-donating group (Fc-NH-CO-) significantly affects the Fc redox potential. On the contrary, spacer and peptide lengths display a moderate effect. We also carried out a conformational study in the crystal state (X-ray diffraction), and in solution (2D-NMR) on three intermediate molecules. Interestingly, the tripeptide Boc-Gly-Gly-Ala-OEt adopts a &#x3b2;-turn structure in all environments. This finding help to explain its resistance to the enzymatic hydrolysis. Enzymatic degradation tests in human serum were performed on the other conjugates as well, highlighting that the Fc unit acts as a protector of the peptide portion.</p>
</abstract>
<kwd-group>
<kwd>cyclic voltammetry</kwd>
<kwd>enzymatic degradation</kwd>
<kwd>ferrocene</kwd>
<kwd>peptide</kwd>
<kwd>X-ray structure</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Universit&#xe0; degli Studi di Padova</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100003500</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. BB, FF, and SS are grateful to the Italian Ministry of Research for the financial support through PRIN 2020 NO. 2020833Y75.</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="39"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Bioinorganic Chemistry</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<label>1</label>
<title>Introduction</title>
<p>Ferrocene derivatives have attracted considerable interest as anticancer, antibacterial, antifungal and antiparasitic drugs (<xref ref-type="bibr" rid="B35">Wang and Astruc, 2025</xref>; <xref ref-type="bibr" rid="B26">Ornelas and Astruc, 2023</xref>; <xref ref-type="bibr" rid="B27">Patra and Gasser, 2017</xref>; <xref ref-type="bibr" rid="B14">Gasser et al., 2011</xref>). In recent years we synthesized a variety of ferrocene-peptide conjugates with the aim at studying how the peptide skeleton affects charge and/or electron transfer. (<xref ref-type="bibr" rid="B5">Biondi et al., 2022</xref>; <xref ref-type="bibr" rid="B6">Bisello et al., 2023</xref>; <xref ref-type="bibr" rid="B12">Donoli et al., 2011</xref>; <xref ref-type="bibr" rid="B30">Santi et al., 2021</xref>; <xref ref-type="bibr" rid="B31">Santi et al., 2022</xref>). In those studies, the ferrocene (Fc) unit was linked to the peptides <italic>via</italic> amide bond but in two different ways: N-linked, Fc-NH-CO-, or C-linked Fc-CO-NH. The different bonding mode resulted in an important decrease of Fc oxidation potential (of around 300&#x2013;400&#xa0;mV) from an electron-withdrawing group (-CO-NH-) to an electron-donating one (-NH-CO-).</p>
<p>Fc is a reliable and easy-to-handle electrochemical probe, but it is also able to promote the generation of reactive oxygen species (ROS) under physiological conditions. ROS concentrations higher than normal favor carcinogenesis, but at too elevated levels cytotoxic effects are observed. Indeed, literature reports refer of Fc-conjugates displaying anticancer activities (<xref ref-type="bibr" rid="B21">Ludwig, et al., 2021</xref>; <xref ref-type="bibr" rid="B23">Mooney et al., 2009</xref>; <xref ref-type="bibr" rid="B39">Zhou et al., 2012</xref>).</p>
<p>Recent studies have established that cellular uptake involves the internalization of ferrocene bound to transferrin, a plasma membrane transporter protein that mediates cellular iron uptake. This protein, as validated by a recent molecular docking study, can transport other metal ions or organometallic compounds from the bloodstream to all tissues. Furthermore, these studies have established that intrinsic apoptosis, also known as the mitochondrial pathway, is the primary mechanism driving ferrocene-triggered programmed cell death in tumor cells (<xref ref-type="bibr" rid="B8">Chaudhary et al., 2024</xref>). Furthermore ferroptosis, a different cell death pathway, is currently a subject of intense study for which it is well established that it involves iron-dependent lipid peroxidation and cell membrane damage (<xref ref-type="bibr" rid="B22">Meoli et al., 2025</xref>).</p>
<p>Tumor cells actively modify their metabolic pathways to meet their energy needs and maintain uncontrolled growth and proliferation. They display elevated levels of ROS due to oncogenic modification, which also leads to increased metabolism and mitochondrial dysfunction compared to healthy cells. Oncogenic cells are well-adapted to increase ROS levels by activating antioxidant pathways. However, ROS overload can cause negative consequences, including the oxidation of cell membranes, enzymes, or DNA, leading to cell death. Therefore, the increase of ROS concentration can be exploited as a cancer therapy. To this aim, two approaches can be envisaged: the first involves inhibiting the protective mechanisms developed by tumor cells, while the second involves the exogenous production of ROS, for example, through chemotherapy or radiotherapy.</p>
<p>The stress-induced damage of ferrocene activates an apoptotic signaling program that drives cell death, mediated by mitochondrial proteins, through the formation of pores on the outer mitochondrial membrane. However, higher levels of ROS can also trigger autophagy (<xref ref-type="bibr" rid="B8">Chaudhary et al., 2024</xref>). Therefore, apoptosis and autophagy play an essential role in the cell death cycle. Activating these mechanisms, however, requires an overload of ROS, which occurs because ferrocene and its derivatives can donate electrons to natural substrates, such as H<sub>2</sub>O<sub>2</sub>, a product of normal cellular metabolism, leading to the formation of highly toxic hydroxyl radicals (HO&#x22c5;) (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B35">Wang and Astruc, 2025</xref>; <xref ref-type="bibr" rid="B37">Xu et al., 2022</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Mechanism of ROS production by Fc-containing substrates (<xref ref-type="bibr" rid="B35">Wang and Astruc, 2025</xref>).</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g001.tif">
<alt-text content-type="machine-generated">Chemical reaction diagram involving a ferrocene. Fe(II) reacts with hydrogen peroxide (H&#x2082;O&#x2082;) to form Fe(III), hydroxide ion (OH&#x207B;), and hydroxyl radical (HO&#xB7;). Fe(III) then reacts with H&#x2082;O&#x2082; and OH&#x207B; to regenerate Fe(II), with water (H&#x2082;O) and hydroperoxyl radical (HOO&#xB7;) as products.</alt-text>
</graphic>
</fig>
<p>This property of Fc has been used to design various types of anticancer therapies. Early studies highlighted that a challenge to overcome for Fc application in medicine is its poor water solubility, being a particularly hydrophobic molecule.</p>
<p>It was shown that even if the lipophilic sandwich ligands allow the penetration through biological membranes, the water solubility is very important to the distribution of the drug into the organism (<xref ref-type="bibr" rid="B24">Neuse and Kanzawa, 1990</xref>). Both Fe(III) and Fe(II) derivatives could exhibit antitumor properties. Since Fc derivatives have long been known for their anticancer activities, the redox stability of both redox forms in biological media is a key aspect for their pharmacological applications. The lipophilic neutral Fe(II) form allows for transferring the derivative through biological membranes, whereas the cationic Fe(III) form provides solubility in hydrophilic media (<xref ref-type="bibr" rid="B26">Ornelas and Astruc, 2023</xref>).</p>
<p>Therefore, structures in which Fc is conjugated to a peptide that helps increase its solubility in the physiological environments have been studied for a long time (<xref ref-type="bibr" rid="B25">Ornelas, 2011</xref>).</p>
<p>Moreover, by exploiting electronic communication between organometallic fragments, it is possible to obtain optimized oligoferrocenes with redox potentials lower than those of the original ferrocenes. Fc cytotoxic activity is mediated by its ability to generate ROS as its redox potential (&#x2b;0.4&#xa0;V vs. SCE) is compatible with the intracellular values, which range from &#x2b;0.40&#xa0;V to &#x2212;0.44&#xa0;V vs. SCE (<xref ref-type="bibr" rid="B20">Kovacic et al., 1988</xref>; <xref ref-type="bibr" rid="B19">Kovacic, 2007</xref>).</p>
<p>However, the oxidation process is strongly influenced by the substituents attached to the cyclopentadienyl (Cp) rings, which modify their electronic distribution. For example, for the compound Fc-CO-Ala-Ala-OEt (<xref ref-type="fig" rid="F2">Figure 2A</xref>) an <italic>E</italic>
<sup>0&#x2019;</sup> value (&#x2248;<italic>E</italic>
<sub>1/2</sub>) of 0.630&#xa0;V vs. SCE is found, indicating that the presence of the dipeptide inhibits the oxidation of iron (<xref ref-type="bibr" rid="B3">Bauer et al., 1999</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Fc-CO-Ala-Ala-OEt, <bold>(B)</bold> 4-Fc-benzoyl-Gly-Ala-OEt and <bold>(C)</bold> 6-Fc-2-naphthoil-Gly-Ala-OEt.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g002.tif">
<alt-text content-type="machine-generated">Chemical structures labeled A, B, and C. (A) and (C) depict ferrocene- derived peptidyl structures ending with Ala-Ala-OEt, while (B) shows a structure ending with Gly-Ala-OEt. Red highlights the peptide bonds and aromatic rings, with Fc indicating a ferrocene moiety.</alt-text>
</graphic>
</fig>
<p>This effect is due to the electron-withdrawing action of the carbonyl group, which depletes part of the electron density of Fc. Under these conditions, iron oxidation would lead to an additional positive charge that would add to the previous effect, making the complex more difficult to oxidize.</p>
<p>At variance, the oxidation potentials of 4-Fc-benzoyl-Gly-Ala-OEt (<xref ref-type="bibr" rid="B16">Harry et al., 2014</xref>) (<xref ref-type="fig" rid="F2">Figure 2B</xref>) and 6-Fc-2-naphthoyl-Ala-Ala-OEt (<xref ref-type="bibr" rid="B23">Mooney et al., 2009</xref>) (<xref ref-type="fig" rid="F2">Figure 2C</xref>) are significantly lower (0.473 and 0.442&#xa0;V vs. SCE respectively), due to the presence of the aromatic spacers which distances Fc from the carbonyl group (reduced inductive effect) thus leaving a sufficient electron density on Fc. Therefore, Fc is more easily oxidized in a cellular environment. While the electron-withdrawing power of the carbonyl increases the oxidation potential, an aromatic moiety leaves it almost unaffected, in view of the extended conjugation of the &#x3c0;-electrons of the Cp rings that permits the oxidation of Fc under physiological conditions.</p>
<p>These considerations urged us to explore different conjugation moieties to Fc, in order to fine tuning its ability to promote ROS production in cells. Our aim was to favor electron-donating groups to maintain the redox potential at approximately &#x2b;0.4&#xa0;V (vs. SCE) or, even better, to lower it. We then herein report synthesis, characterization, enzyme degradation assays and, most importantly, an in-depth cyclic voltammetry study of six new, Fc-conjugated molecules (<xref ref-type="table" rid="T1">Table 1</xref>), characterized by a Fc-N connections and by spacer and peptide units of different lengths.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Compounds studied in this work.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">ID</th>
<th align="left">Compound</th>
<th align="left">Molecular structure</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<bold>Fc</bold>
</td>
<td align="left">Ferrocene</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx1.tif">
<alt-text content-type="machine-generated">Chemical structure showing a ferrocene (Fc) group connected to a hydrogen atom. The Fc is encircled in blue, and the hydrogen is linked with a red line.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>1</bold>
</td>
<td align="left">N-Fc-succinic monoamide acid</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx2.tif">
<alt-text content-type="machine-generated">Chemical structure of a molecule featuring a ferrocene (Fc) moiety bonded to an amide group, followed by a three-carbon chain terminating with a carboxylic acid group. The ferrocene is highlighted in blue, while the amide and carboxylic acid groups are marked in red.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>2</bold>
</td>
<td align="left">N-Fc-succinamide-Gly-Ala-OEt</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx3.tif">
<alt-text content-type="machine-generated">Chemical structure of a peptide bond containing a ferrocene (Fc) group highlighted in a blue circle. The structure includes amide bonds, carbonyl groups, and a methoxy group.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>3</bold>
</td>
<td align="left">N-Fc-glutaric monoamide acid</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx4.tif">
<alt-text content-type="machine-generated">Chemical structure of ferrocene-glutamic acid conjugate. It features a ferrocene group (Fc) linked to a glutamic acid derivative. The structure includes a nitrogen (NH) and two oxygen double bonds highlighted in red, with a hydroxyl (OH) group on the right.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>4</bold>
</td>
<td align="left">N-Fc-glutaramide-Gly-Ala-OEt</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx5.tif">
<alt-text content-type="machine-generated">Chemical structure of a compound featuring a ferrocene unit, depicted as &#x22;Fc&#x22; within a blue circle, linked to a long chain with alternating bonds and functional groups, including an amide and ester.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>5</bold>
</td>
<td align="left">N-Fc-pimelamide-Gly-Ala-OEt</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx6.tif">
<alt-text content-type="machine-generated">Chemical structure of a compound featuring a ferrocene moiety (Fc) bonded to a chain with carbon, oxygen, nitrogen, and hydrogen atoms. It includes functional groups like amide, ketone, and ester, with colored highlights for specific elements or bonds.</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>6</bold>
</td>
<td align="left">N-Fc-glutaramide-Gly-Gly-Ala-OEt</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx7.tif">
<alt-text content-type="machine-generated">Chemical structure of a ferrocene (Fc) peptide. The structure includes a ferrocene group linked to an amide bond (NH) and a peptide chain with multiple amide bonds and carbonyl groups (C=O). It ends with a methyl ester group (CH&#x2083;).</alt-text>
</inline-graphic>
</td>
</tr>
<tr>
<td align="left">
<bold>Fc-NH</bold>
<sub>
<bold>2</bold>
</sub>
</td>
<td align="left">Aminoferrocene</td>
<td align="left">
<inline-graphic xlink:href="fchbi-05-1736812-fx8.tif">
<alt-text content-type="machine-generated">Chemical structure representation of ferrocene amine. The ferrocene (Fc) component is enclosed in a blue circle, connected to an amine group (NH&#x2082;) in red, indicating its chemical bond.</alt-text>
</inline-graphic>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec sec-type="materials|methods" id="s2">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2-1">
<label>2.1</label>
<title>Peptide syntheses</title>
<p>Syntheses were carried out in an oxygen and moisture-free atmosphere. Solvents were dried by reflux over the appropriate drying agent and distilled under a stream of argon. Fc, Fc-NH<sub>2</sub>, 1-hydroxy-benzotriazole hydrate (HOBt), diisopropylethylamine (DIEA), succinic anhydride, glutaric anhydride and pimelic acid were Sigma Aldrich products; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), and L-alanine ethyl ester hydrochloride (H-L-Ala-OEt&#xb7;HCl) were Iris Biotech products. Boc-Gly-L-Ala-OEt was prepared by literature procedures.</p>
</sec>
<sec id="s2-2">
<label>2.2</label>
<title>Mass spectrometry</title>
<p>MS spectra were obtained using an Agilent 6130 ESI-TOF mass spectrometer coupled to an HPLC system, collecting data in the positive mode. All compounds were analyzed by analytical HPLC and were &#x3e;95% pure.</p>
</sec>
<sec id="s2-3">
<label>2.3</label>
<title>NMR spectra</title>
<p>Spectra were collected on a Bruker Avance III HD spectrometer operating at 400.13&#xa0;MHz (T &#x3d; 298K). The peptide concentration in solution was 1&#xa0;mM in spectrograde CHCl<sub>3</sub>-d<sub>1</sub> (99.8% D containing 0.5 %wt. of silver foils as stabilizers and 0.03% (v/v) tetramethylsilane&#x2013;Eurisotop) and DMSO-d<sub>6</sub> (99.96% D&#x2013;Eurisotop). Processing and evaluation of the experimental data were carried out using the TOPSPIN software packages. All homonuclear spectra were acquired by collecting 400 experiments, each consisting of 32 scans and 2K data points. The spin systems of the amino acid residues were identified using standard double-quantum filtered COSY (<xref ref-type="bibr" rid="B29">Rance et al., 1983</xref>) and clean TOCSY (<xref ref-type="bibr" rid="B15">Griesinger et al., 1988</xref>) spectra. In the latter case, the spin-lock sequence was 70&#xa0;ms long. NOESY experiments were utilized for sequence-specific assignments (<xref ref-type="bibr" rid="B36">W&#xfc;thrich, 1991</xref>; <xref ref-type="bibr" rid="B7">Boros et al., 2018</xref>).</p>
</sec>
<sec id="s2-4">
<label>2.4</label>
<title>X-ray diffraction</title>
<p>Data for <bold>1</bold> and N-ferrocenylsuccinimide (<bold>Fc-Su</bold>), obtained as byproduct in the synthesis of <bold>2</bold>, were collected using an Oxford Diffraction Gemini E diffractometer, equipped with a 2 K &#xd7; 2 K EOS CCD area detector and sealed&#x2013;tube Enhance (Cu-K&#x3b1;, &#x3bb; &#x3d; 1.54178&#xa0;&#xc5;) X&#x2013;ray source. Data for compound <bold>3</bold> were collected on a Bruker D8 Venture diffractometer equipped with Incoatec I&#x3bc;S3.0 (EF) microfocus sealed-tube (Cu-K&#x3b1;, &#x3bb; &#x3d; 1.54178&#xa0;&#xc5;), a Montel layer optics monochromator, and a Photon III C14 CPAD area detector. Data reduction, finalization and cell refinement were carried out through the CrysAlisPro software. Empirical multi-scan absorption corrections using equivalent reflections have been performed with the scaling algorithm SCALE3 ABSPACK. Accurate unit cell parameters were obtained by least squares refinement of the angular settings of strongest reflections, chosen from the whole experiment. The structures were solved with Olex2 (<xref ref-type="bibr" rid="B11">Dolomanov et al., 2009</xref>) by using ShelXT structure solution program by Intrinsic Phasing and refined with the ShelXL refinement package using least-squares minimization (<xref ref-type="bibr" rid="B32">Sheldrick, 2015</xref>). In the last cycles of refinement, non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in calculated positions, and a riding model was used for their refinement. <xref ref-type="sec" rid="s13">Supplementary Table S1</xref> reports the crystal data and refinement details. Cambridge Crystallographic Data Centre (CCDC) numbers 2497229-2497,231 contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint CCDC and Fachinformationszentrum Karlsruhe Access Structures service <ext-link ext-link-type="uri" xlink:href="http://www.ccdc.ca-m.ac.uk/structures">www.ccdc.ca-m.ac.uk/structures</ext-link>.</p>
</sec>
<sec id="s2-5">
<label>2.5</label>
<title>Cyclic voltammetry</title>
<p>The experiments were performed in an air-tight three-electrode cell connected to a vacuum/argon Schlenk line. Dichloromethane solvent was pre-dried with anhydrous calcium chloride, refluxed over calcium hydride and distilled under a stream of Argon. Solvent and <italic>n</italic>Bu<sub>4</sub>NPF<sub>6</sub> were degassed in a Schlenk flask by manifold freeze-pump-thaw cycles and transferred by cannula in the cell. The reference electrode was a SCE (Tacussel ECS C10) separated from the solution by a bridge compartment filled with the same solvent/supporting electrolyte solution used in the cell. The counter electrode was a platinum spiral with around 1&#xa0;cm<sup>2</sup> apparent surface area. The working electrode was a disk obtained from cross section of a gold wire with 0.5 and 0.125&#xa0;mm diameter sealed in glass. Between successive scans, the working electrode was polished on alumina according to standard procedures and sonicated before use. An, E.G.,&#x26;G PAR-175 signal generator was used. The currents and potentials were recorded on a Lecroy 9310L oscilloscope. The potentiostat was home-built with a positive feedback loop for compensation of the ohmic drop (<xref ref-type="bibr" rid="B2">Amatore et al., 1989</xref>).</p>
</sec>
<sec id="s2-6">
<label>2.6</label>
<title>Peptide stability in serum</title>
<p>The peptides were dissolved in DMSO at a concentration of 5&#xa0;mg/mL. In Eppendorf tubes, 1&#xa0;mL of HEPES buffer (25&#xa0;mM, pH &#x3d; 7.6) was temperature equilibrated at 37&#xa0;&#xb0;C before adding 250&#xa0;&#x3bc;L of human serum and 20&#xa0;&#x3bc;L of peptide solution. The human serum used in these experiments was obtained from Merck. It is derived from platelet-poor human plasma. It is sterile-filtered and tested for viruses and <italic>mycoplasma</italic>. The reaction was monitored for 24&#xa0;h. At fixed intervals, 100&#xa0;&#x3bc;L of the solution was withdrawn and added with 200&#xa0;&#x3bc;L of absolute ethanol. The sample was kept on ice for 15&#xa0;min and then centrifuged at 16,000&#xa0;g for 5&#xa0;min. Finally, the supernatant solution was analyzed by HPLC or HPLC&#x2013;MS. (<xref ref-type="bibr" rid="B18">Jenssen and Aspmo, 2008</xref>). A peptide of similar length, not resistant to degradation in serum, was used as a positive test. The peptide sequence is as follows: Tyr-Ser-Ser-Phe-Leu. To verify peptide stability in buffer solution, samples containing peptide solutions, buffer, and ethanol were also analyzed.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<label>3</label>
<title>Results and discussion</title>
<sec id="s3-1">
<label>3.1</label>
<title>Synthesis and structural determinations</title>
<p>Compounds <bold>1</bold>-<bold>6</bold> (<xref ref-type="table" rid="T1">Table 1</xref>) were synthesized by solution methods and characterized by HPLC-MS and NMR spectrometry as described in detail in the Supplementary Material file. Briefly, peptide bonds were formed by activating the carboxylic function with the coupling reagents EDC/HOBt [EDC, N-ethyl-N&#x2032;-dimethylaminopropyl-carbodiimide; HOBt, 1-hydroxybenzotriazole]. HOBt suppresses racemization, when chiral amino acids are involved, but it also catalyzes the formation of amide bonds (<xref ref-type="bibr" rid="B9">Crisma et al., 1998</xref>). For this latter reason it was used even when chirality was not an issue. The amide bonds of compounds <bold>1</bold> and <bold>3</bold> were prepared by reacting Fc-NH<sub>2</sub> with succinic and glutaric anhydride, respectively. In the case of compound <bold>5</bold>, Fc-NH<sub>2</sub> was first reacted with pimelic acid. The product obtained was isolated and, without further purification, reacted with H-Gly-Gly-Ala-OEt (see <xref ref-type="sec" rid="s13">Supplementary Material</xref>).</p>
<p>When <bold>1</bold> was activated with EDC/HOBt to synthesize <bold>2</bold>, we also obtained N-ferrocenylsuccinimide (<bold>Fc-Su</bold>) as a byproduct, due to an intramolecular amide (imide) bond formation (<xref ref-type="sec" rid="s13">Supplementary Material</xref>). The same reaction occurred in the synthesis of <bold>4</bold>, starting from <bold>3</bold>, yielding a moderate amount of N-ferrocenylglutarimide (<xref ref-type="sec" rid="s13">Supplementary Material</xref>). We were able to grow single crystals of both <bold>Fc-Su</bold> and its precursor, compound <bold>1</bold>, and to determine their molecular structures by X-ray diffraction (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> Molecular structure of <bold>1</bold>. <bold>(B)</bold> Molecular structure of <bold>Fc-Su</bold> (symmetry operation: 1 &#x3d; &#x2b;x, 3/2&#x2013;y, &#x2b;z). The thermal ellipsoids are drawn at the 50% probability level.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g003.tif">
<alt-text content-type="machine-generated">Two molecular structures labeled (A) and (B). Structure (A) features an organometallic complex with carbon, hydrogen, nitrogen, oxygen, and iron atoms, with iron at the center. Structure (B) shows a similar complex, highlighting variations in atom positioning and bonds. Both structures emphasize 3D spatial arrangements.</alt-text>
</graphic>
</fig>
<p>The structure of <bold>1</bold> was solved in the monoclinic space group <italic>P</italic>2<sub>1</sub>/<italic>c</italic>, while that of <bold>Fc-Su</bold> was solved in the monoclinic space group <italic>P</italic>2<sub>1</sub>/<italic>m</italic>. In both structures, the cyclopentadienyl rings coordinate to the Fe(II) ion with &#x3b7;<sup>5</sup> hapticity, adopting a nearly eclipsed configuration. Such an arrangement has been previously observed in several ferrocene derivatives (<xref ref-type="bibr" rid="B13">Donoli et al., 2013</xref>; <xref ref-type="bibr" rid="B30">Santi et al., 2021</xref>; <xref ref-type="bibr" rid="B4">Biondi et al., 2021</xref>; <xref ref-type="bibr" rid="B5">Biondi et al., 2022</xref>). The Fe&#x2013;C bond lengths range from 2.025 to 2.045&#xa0;&#xc5;, while the distances between the Fe(II) ion and the centroids of the cyclopentadienyl rings are between 1.642-1.644&#xa0;&#xc5;.</p>
<p>Interestingly, in <bold>1</bold> the angle between the plane of the cyclopentadienyl ring (C6&#x2013;C10) and the plane defined by atoms N1&#x2013;C11&#x2013;O1&#x2013;C12 is 8.3&#xb0;, whereas in <bold>Fc-Su</bold>, the angle between the cyclopentadienyl plane (C4&#x2013;C5&#x2013;C6&#x2013;C5&#x2032;&#x2013;C4&#x2019;) and the succinimide plane is only 0.2&#xb0;. This coplanarity suggests that an extended &#x3c0;-conjugation is established between Cp and the imide of <bold>Fc-Su</bold>. Such conjugation exists also between Cp and the amide in <bold>1</bold>, although to a lower extent.</p>
<p>In compound <bold>1</bold>, the N1&#x2013;H1 and O3&#x2013;H3 groups participate in intermolecular hydrogen bonds with atoms O2 and O1, respectively, as described in <xref ref-type="table" rid="T2">Table 2</xref> and shown in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Hydrogen bonds in <bold>I</bold>; D denotes the donor atom and A the acceptor atom.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">D-H</th>
<th align="left">d (D-H)/&#xc5;</th>
<th align="left">d (H&#xb7;&#xb7;&#xb7;A)/&#xc5;</th>
<th align="left">&#x3c;DHA/&#xb0;</th>
<th align="left">d (D&#xb7;&#xb7;&#xb7;A)/&#xc5;</th>
<th align="left">A</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">O3-H3</td>
<td align="left">0.82</td>
<td align="left">1.849</td>
<td align="left">165.85</td>
<td align="left">2.651</td>
<td align="left">O1<sup>&#xa7;</sup>
</td>
</tr>
<tr>
<td align="left">N1-H1</td>
<td align="left">0.86</td>
<td align="left">2.079</td>
<td align="left">167.68</td>
<td align="left">2.925</td>
<td align="left">O2<sup>&#x23;</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Symmetry operations: &#xa7; &#x3d; -x, y-1/2, -z&#x2b;1/2, &#x23; &#x3d; -x, -y&#x2b;1, -z&#x2b;1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Packing of compound 1 along the a, b and c crystallographic axes, respectively. Only H1 and H3 are shown; all others are omitted for clarity. Dotted red lines represent hydrogen bonds.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g004.tif">
<alt-text content-type="machine-generated">Illustration showing three molecular structures in a grid-like formation. Each structure consists of interconnected geometric shapes represented by gray, blue, and red lines and vertices, indicating the arrangement of atoms. The patterns depict distinct molecular configurations, demonstrating variations in connectivity and spatial orientation.</alt-text>
</graphic>
</fig>
<p>We were also able to solve the crystal structure of Boc-Gly-Gly-Ala-OEt, the tripeptide intermediate used in the synthesis of compound <bold>6</bold>. The structure was determined in the monoclinic space group <italic>P</italic>2<sub>1</sub>. The asymmetric unit comprises two crystallographic independent molecules, designated A and B (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Both molecules feature a <italic>i &#x2192; i&#x2b;3</italic> intramolecular C&#x3d;O&#x22c5;&#x22c5;&#x22c5;H&#x2013;N hydrogen bond, which stabilizes a &#x3b2;-turn conformation. In molecule A, the &#x3c6; and &#x3c8; dihedral angles adopt values close to those characteristics of a type III&#x2019; &#x3b2;-turn, whereas molecule B exhibits negative angles consistent with a type III &#x3b2;-turn (<xref ref-type="table" rid="T3">Table 3</xref>) (<xref ref-type="bibr" rid="B34">Venkatachalam, 1968</xref>). The intramolecular hydrogen bond forms a 10-membered pseudo-cycle with very similar geometries in both molecules, with N&#xb7;&#xb7;&#xb7;O donor&#x2013;acceptor distances of approximately 3.0&#xa0;&#xc5; for A (N3A&#x22c5;&#x22c5;&#x22c5;O2A) and B (N3B&#x22c5;&#x22c5;&#x22c5;O2B) (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> The two crystallographic independent molecules of Boc-Gly-Gly-Ala-OEt. <bold>(B)</bold> Opposite handedness of molecules A and B. <bold>(C)</bold> H-bond supported 1D chain of alternating molecules A and B. Dotted red lines represent H-bonds. The thermal ellipsoids are drawn at the 50% probability level.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g005.tif">
<alt-text content-type="machine-generated">(A) Structural diagrams of Molecules A and B showing atomic connections and hydrogen bonding, marked by dashed lines. (B) 3D representations of both molecules with rotation arrows. (C) Two interacting molecular chains labeled A and B, connected by dashed lines indicating interactions.</alt-text>
</graphic>
</fig>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Selected torsional angles in Boc-Gly-Gly-Ala-OEt.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Angle</th>
<th align="left">Atom 1</th>
<th align="left">Atom 2</th>
<th align="left">Atom 3</th>
<th align="left">Atom 4</th>
<th align="left">Degree</th>
<th align="left">Atom 1</th>
<th align="left">Atom 2</th>
<th align="left">Atom 3</th>
<th align="left">Atom 4</th>
<th align="left">Degree</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">&#x3d5;1</td>
<td align="left">C2A</td>
<td align="left">N1A</td>
<td align="left">C3A</td>
<td align="left">C4A</td>
<td align="left">69.5&#xb0;</td>
<td align="left">C2B</td>
<td align="left">N1B</td>
<td align="left">C3B</td>
<td align="left">C4B</td>
<td align="left">&#x2212;66.77&#xb0;</td>
</tr>
<tr>
<td align="left">&#x3c8;1</td>
<td align="left">N1A</td>
<td align="left">C3A</td>
<td align="left">C4A</td>
<td align="left">N2A</td>
<td align="left">10.5&#xb0;</td>
<td align="left">N1B</td>
<td align="left">C3B</td>
<td align="left">C4B</td>
<td align="left">N2B</td>
<td align="left">&#x2212;15.45&#xb0;</td>
</tr>
<tr>
<td align="left">&#x3d5;2</td>
<td align="left">C4A</td>
<td align="left">N2A</td>
<td align="left">C5A</td>
<td align="left">C6A</td>
<td align="left">72.4&#xb0;</td>
<td align="left">C4B</td>
<td align="left">N2B</td>
<td align="left">C5B</td>
<td align="left">C6B</td>
<td align="left">&#x2212;71.76&#xb0;</td>
</tr>
<tr>
<td align="left">&#x3c8;2</td>
<td align="left">N2A</td>
<td align="left">C5A</td>
<td align="left">C6A</td>
<td align="left">N3A</td>
<td align="left">19.2&#xb0;</td>
<td align="left">N2B</td>
<td align="left">C5B</td>
<td align="left">C6B</td>
<td align="left">N3B</td>
<td align="left">&#x2212;17.69&#xb0;</td>
</tr>
<tr>
<td align="left">&#x3d5;3</td>
<td align="left">C6A</td>
<td align="left">N3A</td>
<td align="left">C7A</td>
<td align="left">C9A</td>
<td align="left">&#x2212;64.1&#xb0;</td>
<td align="left">C6B</td>
<td align="left">N3B</td>
<td align="left">C7B</td>
<td align="left">C9B</td>
<td align="left">&#x2212;87.51&#xb0;</td>
</tr>
<tr>
<td align="left">&#x3c8;3</td>
<td align="left">N3A</td>
<td align="left">C7A</td>
<td align="left">C9A</td>
<td align="left">O6A</td>
<td align="left">144.8&#xb0;</td>
<td align="left">N3B</td>
<td align="left">C7B</td>
<td align="left">C9B</td>
<td align="left">O6B</td>
<td align="left">162.94&#xb0;</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Hydrogen bonds in Boc-Gly-Gly-Ala-OEt; D is the donor atom and A the acceptor atom.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">D-H</th>
<th align="left">d (D-H)/&#xc5;</th>
<th align="left">d (H&#xb7;&#xb7;&#xb7;A)/&#xc5;</th>
<th align="left">&#x3c;DHA/&#xb0;</th>
<th align="left">d (D&#xb7;&#xb7;&#xb7;A)/&#xc5;</th>
<th align="left">A</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">N2A-H2A</td>
<td align="left">0.86</td>
<td align="left">2.107</td>
<td align="left">159.2</td>
<td align="left">2.927</td>
<td align="left">O4B</td>
</tr>
<tr>
<td align="left">N1A-H1A</td>
<td align="left">0.86</td>
<td align="left">2.134</td>
<td align="left">168.59</td>
<td align="left">2.982</td>
<td align="left">O3B</td>
</tr>
<tr>
<td align="left">N3A-H3A</td>
<td align="left">0.86</td>
<td align="left">2.172</td>
<td align="left">160.32</td>
<td align="left">2.995</td>
<td align="left">O2A</td>
</tr>
<tr>
<td align="left">N1B-H1B</td>
<td align="left">0.86</td>
<td align="left">2.096</td>
<td align="left">164.91</td>
<td align="left">2.935</td>
<td align="left">O3A<sup>&#xa7;</sup>
</td>
</tr>
<tr>
<td align="left">N3B-H3B</td>
<td align="left">0.86</td>
<td align="left">2.207</td>
<td align="left">154.39</td>
<td align="left">3.006</td>
<td align="left">O2B</td>
</tr>
<tr>
<td align="left">N2B-H2B</td>
<td align="left">0.86</td>
<td align="left">2.122</td>
<td align="left">161.37</td>
<td align="left">2.95</td>
<td align="left">O4A<sup>&#xa7;</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Symmetry operation: &#xa7; &#x3d; x-1, y, z.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Intermolecular H-bonds connect molecules A and B into a 1D supramolecular chain, arranged in an alternating A&#x2013;B sequence (<xref ref-type="fig" rid="F5">Figure 5C</xref>). This motif is sustained by N1A&#x22c5;&#x22c5;&#x22c5;O3B and N2A&#x22c5;&#x22c5;&#x22c5;O4B H-bonds, along with the reciprocal N1B&#x22c5;&#x22c5;&#x22c5;O3A and N2B&#x22c5;&#x22c5;&#x22c5;O4A interactions (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<p>This &#x3b2;-turn structure was rather unexpected, as Gly usually prefers to adopt extended conformations. We may argue that the &#x3b2;-turn was promoted by the crystal packing and/or by the achiral nature of Gly. Indeed, the two independent molecules exhibit opposite helical handedness and form a pseudo-racemate: molecule A twists anticlockwise and molecule B clockwise (<xref ref-type="fig" rid="F5">Figure 5B</xref>). It is well known that racemates and pseudo-racemates crystallize easily and facilitate structure resolution (<xref ref-type="bibr" rid="B38">Zawadke and Berg, 1993</xref>; <xref ref-type="bibr" rid="B10">Doi et al., 1993</xref>; <xref ref-type="bibr" rid="B33">Toniolo et al., 1994</xref>). However, we are inclined to believe that the observed bended conformation of Boc-Gly-Gly-Ala-OEt does not depend on packing or chirality because it is maintained in solution and also when the tripeptide is linked to Fc. As a matter of fact, typical cross-peaks of turn/helical peptide conformations (<xref ref-type="bibr" rid="B36">W&#xfc;thrich, 1991</xref>) are observed in the NOESY spectrum of <bold>6</bold> in CDCl<sub>3</sub> solution. Both NH<sub>
<italic>i</italic>
</sub> &#x2192; NH<sub>
<italic>i&#x2b;1</italic>
</sub> connectivities characterizing the &#x3b2;-turn are clearly detected (<xref ref-type="fig" rid="F6">Figure 6</xref>). Since the &#x3b2;-turn involves the two achiral Gly residues, the left- and right-turn form likewise with the same probability. However, we are unable to assess if one conformation prevails over the other because they interconvert at a much faster rate than the NMR time scale (<xref ref-type="bibr" rid="B17">Hummel et al., 1987</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Section of the NOESY spectrum of <bold>6</bold>&#xa0;at 1 mM concentration in CDCl<sub>3</sub> solution.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g006.tif">
<alt-text content-type="machine-generated">Contour plot of a 2D NMR spectrum showing interactions between glycine and alanine hydrogen atoms. Black contours represent various intensity levels, with annotations for Gly&#xB9; HN-Gly&#xB2; HN and Gly&#xB2; HN-Ala HN interactions on axes labeled F&#x2081; and F&#x2082; for hydrogen ppm values.</alt-text>
</graphic>
</fig>
<p>Moreover, the stable presence in solution of such &#x3b2;-turn could account for the fair resistance to enzymatic degradation of compound <bold>6</bold> (see below).</p>
</sec>
<sec id="s3-2">
<label>3.2</label>
<title>Cyclic voltammetry analysis</title>
<p>Fc is a very useful redox probe as it is stable in water, it is insensitive to air in both neutral and oxidized states, it is soluble in common organic solvents and in addition it displays a low oxidation potential. As previously pointed out, the way Fc binds to an organic moiety significantly influences its redox potential. To better understand this issue, we prepared the above-mentioned Fc-conjugates, that differ for spacer and peptide length, but share the way Fc is connected, <italic>i.e.</italic>, the amide nitrogen (Fc-NH-CO-). The most exploited way to conjugate Fc to a peptide for creating new drugs has been so far Fc-CO-NH-. With our new molecules, we expect to lower the Fc redox potentials below the original ferrocene values, and thus make them compatible with the intracellular redox potentials, which range from &#x2b;0.40&#xa0;V to &#x2212;0.44&#xa0;V vs. SCE.</p>
<p>The cyclic voltammograms of the peptides N-Fc-succinamide-Gly-Ala-OEt (<bold>2</bold>), N-Fc-glutaramide-Gly-Ala-OEt (<bold>4</bold>), N-Fc-pimelamide-Gly-Ala-OEt (<bold>5</bold>), N-Fc-glutaramide-Gly-Gly-Ala-OEt (<bold>6</bold>), and of the carboxylic acids <bold>Fc</bold> (<bold>1</bold>) and <bold>Fc-NH</bold>
<sub>
<bold>2</bold>
</sub> (<bold>3</bold>) are reported in <xref ref-type="fig" rid="F7">Figure 7</xref>. All measurements were performed in dichloromethane solution in the presence of (nBu)<sub>4</sub>BPF<sub>6</sub> (0.1&#xa0;M) as a supporting electrolyte.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Cyclic voltammetry of <bold>1</bold>-<bold>6</bold>, <bold>Fc</bold> and <bold>Fc-NH</bold>
<sub>
<bold>2</bold>
</sub> in CH<sub>2</sub>Cl<sub>2</sub> containing 0.1&#xa0;M <italic>n</italic>Bu<sub>4</sub>NPF<sub>6</sub> as the supporting electrolyte [Au disk electrode (<italic>d</italic> &#x3d; 0.5&#xa0;mm); scan rate 0.2 Vs<sup>-1</sup>; <italic>T</italic> 20&#xa0;&#xb0;C]. The current <italic>i</italic> is normalized according to the equation: <italic>iv</italic>
<sup>-1</sup>
<italic>c</italic>
<sup>-1</sup>, with concentration <italic>c</italic> in the range 2.6&#x2013;2.7&#xa0;mM.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g007.tif">
<alt-text content-type="machine-generated">Three cyclic voltammetry graphs display current versus potential (V vs SCE). The left graph features Fc, Fc-NH2, compound one, and two. The middle graph shows Fc, Fc-NH2, compounds three, four, and six. The right graph presents Fc, Fc-NH2, and compound five. Each graph uses distinct colored lines representing different compounds.</alt-text>
</graphic>
</fig>
<p>The main objective was to evaluate the effect exerted on the oxidation potential (<italic>E</italic>
<sub>1/2</sub>) by the -NHCO- group, the spacer and the peptide and consequently to assess the suitability of these compounds to meet the intracellular redox conditions. The electron-donating properties of the -NHCO- group determine a decrease of the oxidation potential of Fc down to 0.3&#xa0;V for some of our molecules (<xref ref-type="table" rid="T5">Table 5</xref>). On the contrary, the electron-withdrawing effect of the -CONH- group causes an increase in the oxidation potential up to values of 0.6&#x2013;0.8&#xa0;V (see, for example, <xref ref-type="bibr" rid="B5">Biondi et al., 2022</xref>), which are not compatible with the intracellular environment (between 0.40 and &#x2212;0.44&#xa0;V vs. SCE).</p>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Electrochemical data: <italic>E</italic>
<sub>p</sub> &#x3d; peak potential (anodic), <italic>E</italic>
<sub>p/2</sub> &#x3d; potential at <italic>i</italic> &#x3d; <italic>i</italic>
<sub>p/2</sub>, <italic>E</italic>
<sub>1/2</sub> &#x3d; <italic>E</italic>
<sub>p/2</sub> &#x2b; &#x394;<italic>E</italic>
<sub>p</sub>/2 half-wave potential, &#x394;<italic>E</italic>
<sub>p</sub> &#x3d; <italic>E</italic>
<sub>p</sub> - <italic>E</italic>
<sub>p/2</sub>, &#x3b4;<italic>E</italic> &#x3d; &#xb1; 2&#xa0;mV. Potential scanning speed <italic>v</italic> &#x3d; 0.2 Vs<sup>-1</sup>. The current is normalized according to the equation <italic>iv</italic>
<sup>-1/2</sup>
<italic>c</italic>
<sup>-1</sup>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">ID</th>
<th align="left">Compund</th>
<th align="left">
<italic>E</italic>
<sub>p</sub> (V)</th>
<th align="left">
<italic>E</italic>
<sub>p/2</sub> (V)</th>
<th align="left">
<italic>E</italic>
<sub>1/2</sub> (V)</th>
<th align="left">&#x394;<italic>E</italic>
<sub>p</sub> (mV)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<bold>Fc</bold>
</td>
<td align="left">Ferrocene</td>
<td align="left">0.45</td>
<td align="left">0.39</td>
<td align="left">0.42</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">
<bold>1</bold>
</td>
<td align="left">N-Fc-succinic monoamide acid</td>
<td align="left">0.36</td>
<td align="left">0.30</td>
<td align="left">0.33</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">
<bold>2</bold>
</td>
<td align="left">N-Fc-succinamide-Gly-Ala-OEt</td>
<td align="left">0.34</td>
<td align="left">0.28</td>
<td align="left">0.31</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">
<bold>3</bold>
</td>
<td align="left">N-Fc-glutaric monoamide acid</td>
<td align="left">0.33</td>
<td align="left">0.27</td>
<td align="left">0.30</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">
<bold>4</bold>
</td>
<td align="left">N-Fc-glutaramide-Gly-Ala-OEt</td>
<td align="left">0.35</td>
<td align="left">0.29</td>
<td align="left">0.32</td>
<td align="left">70</td>
</tr>
<tr>
<td align="left">
<bold>5</bold>
</td>
<td align="left">N-Fc-pimelamide-Gly-Ala-OEt</td>
<td align="left">0.33</td>
<td align="left">0.27</td>
<td align="left">0.30</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">
<bold>6</bold>
</td>
<td align="left">N-Fc-glutaramide-Gly-Gly-Ala-OEt</td>
<td align="left">0.34</td>
<td align="left">0.28</td>
<td align="left">0.31</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">Fc-NH<sub>2</sub>
</td>
<td align="left">Aminoferrocene</td>
<td align="left">0.11</td>
<td align="left">0.05</td>
<td align="left">0.08</td>
<td align="left">60</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>It can be observed that all the products analyzed show a single, reversible, Nernstian monoelectronic oxidation wave (&#x394;<italic>E</italic>p &#x3d; 60&#x2013;70&#xa0;mV, <xref ref-type="table" rid="T5">Table 5</xref>) in the scan rate <italic>v</italic> range between 0.1 and 5 V<italic>s</italic>
<sup>-1</sup>, on electrode gold disc working with diameter <italic>d</italic> &#x3d; 0.125&#xa0;mm (0.5&#x2013;5 <italic>Vs</italic>
<sup>-1</sup>) and 0.5&#xa0;mm (0.1&#x2013;0.5 Vs<sup>-1</sup>).</p>
<p>As expected, the <italic>E</italic>
<sub>1/2</sub> values demonstrate that the Fc-NH-CO- linkage, <italic>i.e.</italic>, Fc directly connected to N, has the major effect on the oxidation potential of our Fc-peptides, anticipating by 100&#x2013;120&#xa0;mV with respect to <bold>Fc</bold>, with the greatest decrease obtained for peptide <bold>5</bold>. Apparently, a long spacer helps decrease the <italic>E</italic>
<sub>1/2</sub> values, probably because it moves far apart the second, electron-withdrawing carbonyl. This conclusion agrees with the behavior of <bold>1</bold> and <bold>3</bold>, as the latter endowed with a longer chain displays a 30&#xa0;mV reduction of <italic>E</italic>
<sub>1/2</sub>.</p>
<p>The length of the peptides also appears to have an effect, albeit a moderate one. The <italic>E</italic>
<sub>1/2</sub> value of <bold>6</bold>, containing a tripeptide, is slightly lower than in the case of <bold>4</bold>, a conjugate with a dipeptide.</p>
<p>Overall, all Fc-peptides (<bold>2</bold> and <bold>4</bold>&#x2013;<bold>6</bold>) have shown to possess redox values compatible with the intracellular potentials.</p>
</sec>
<sec id="s3-3">
<label>3.3</label>
<title>Peptide enzymatic degradation</title>
<p>The stability of Fc-peptide conjugates against proteolytic degradation is a major challenge in their development as potential anticancer agents. In this study, we investigated the stability of the synthetic peptides when exposed to human serum. After incubation with serum, the integrity of the conjugates was monitored by HPLC. Proteolytic degradation is reported as a function of time (<xref ref-type="bibr" rid="B28">Peggion et al., 2025</xref>; <xref ref-type="bibr" rid="B1">Albini, et al., 2025</xref>).</p>
<p>Considering the dipeptide Gly-Ala conjugated to Fc via linkers of different lengths, we observed rapid degradation of <bold>4</bold>, whereas <bold>2</bold> exhibited a slower degradation rate (<xref ref-type="fig" rid="F8">Figure 8</xref>). We concluded that the Fc moiety exerts a protective effect on the Gly-Ala sequence, depending on the distance between the Fc moiety and the peptide.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Proteolytic degradation in human serum of the peptides <bold>2</bold>, <bold>4</bold> and <bold>6</bold>, represented as the percentage of intact peptide over time calculated as the HPLC-peak area.</p>
</caption>
<graphic xlink:href="fchbi-05-1736812-g008.tif">
<alt-text content-type="machine-generated">Line graph showing the percentage of intact peptide over time in minutes for three conditions: 6 (black squares), 4 (red circles), and 2 (blue triangles). Condition 4 rapidly declines to zero within 30 minutes. Condition 2 decreases steadily over 360 minutes. Condition 6 declines gradually and stabilizes near 50%.</alt-text>
</graphic>
</fig>
<p>Surprisingly, a notably different pattern of degradation was observed for <bold>6</bold>. Here, the peptide moiety is represented by the Gly-Gly-Ala sequence, and the Fc unit is connected to the peptide via the same linker as in compound <bold>4</bold>. In this case, the percentage of intact peptide was around 60% after 3&#xa0;h, and almost 30% of the peptide was still present after 24&#xa0;h (data not shown). The conformational analysis conducted on the free peptide and on <bold>6</bold> revealed the presence of a &#x3b2;-turn structure. This structural feature led us to interpret the observed resistance to proteolysis as an effect of conformational stability rather than the protective role of the Fc moiety.</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Structure-property relationships</title>
<p>The most important structural feature of our new Fc-peptides is the presence of the Fc-NH-CO- moiety, whereas the most exploited way of connection has been so far Fc-CO-NH-. Indeed, with such modification we observed a relevant decrease (about 0.3&#xa0;V) in the oxidation potential due to the electron donating properties of the nitrogen atom. Therefore, Fc-peptides <bold>2</bold> and <bold>4</bold>&#x2013;<bold>6</bold>, endowed with redox values compatible with the intracellular potentials, might result to be good candidates for developing new and effective antitumor agents.</p>
<p>With our new compounds we can also evaluate a possible influence of the spacer on the Fc redox potential. As compared to the effect of the Fc-NH-CO- group, the spacer appears to be of lesser importance, although a small reduction in the redox potential is anyway observed when comparing <bold>1</bold> with <bold>3</bold> and <bold>2</bold> (or <bold>4</bold>) with <bold>5</bold>. As previously stated, such reduction in <bold>3</bold> and <bold>5</bold> (compounds with the longest spacers) is likewise due to the larger separation between Fc and the electron-withdrawing C&#x3d;O at the end of the spacer. In any case, despite its marginal influence on the Fc oxidation we believe that a spacer should be maintained, as clearly demonstrated by previous work (<xref ref-type="bibr" rid="B39">Zhou et al., 2012</xref>).</p>
<p>At variance, a too long spacer may hamper the protection exerted by Fc against the enzymatic degradation of the peptide moieties. Indeed, <bold>4</bold> is rapidly degraded by enzymes, whereas <bold>2</bold> with just one methylene less in the spacer exhibited a slower degradation rate. However, compound <bold>6</bold> characterized by the same spacer of <bold>4</bold> but having a tripeptide instead of a dipeptide regains enzymatic stability. Most probably, this resistance is due to the folded structure (a &#x3b2;-turn) adopted by the tripeptide both in solution (see NMR analysis) and in the crystal state (see X-ray diffraction analysis).</p>
<p>In addition, this folded structure has a moderate effect also on the Fc redox potentials because in a &#x3b2;-turn the amide carbonyls are parallelly aligned (as in the &#x3b1;- and 3<sub>10</sub>-helix) and oriented with the carbonyl oxygen pointing towards the C-terminus of the peptide. In such a disposition a macrodipole forms, with the partial positive charge located at the N-terminus side of the tripeptide, <italic>i.e.</italic>, close to the Fc unit (<xref ref-type="bibr" rid="B12">Donoli et al., 2011</xref>; <xref ref-type="bibr" rid="B4">Biondi et al., 2021</xref>; <xref ref-type="bibr" rid="B31">Santi et al., 2022</xref>). Thus, a longer helical peptide, with a higher dipole moment, is expected to decrease even more the <italic>E</italic>
<sub>1/2</sub> value of Fc.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<label>5</label>
<title>Conclusion</title>
<p>The electrochemical investigation carried out on our newly synthesized Fc-conjugates reveals that the way Fc is connected to the peptide (Fc-NH-CO-) plays the major role in bringing the Fc oxidation potential closer to that of physiological environments. The length of the spacer and of the peptide appears to have an effect as well, but of lesser importance. However, our finding on the influence of a single &#x3b2;-turn suggests that the use of longer, helical peptides will undoubtedly increase the impact on the Fc oxidation, because they generate a larger macrodipole (<xref ref-type="bibr" rid="B12">Donoli et al., 2011</xref>; <xref ref-type="bibr" rid="B13">Donoli et al., 2013</xref>; <xref ref-type="bibr" rid="B4">Biondi et al., 2021</xref>; <xref ref-type="bibr" rid="B31">Santi et al., 2022</xref>). Therefore, by combining the nature of the Fc connection with the lengths of spacer and peptide we can better design Fc-constructs able to act as anticancer drugs. Starting from these results, we now plan to move a step forward. We expect to be able to identify lead compounds with potential anticancer activity by designing a second generation of Fc-peptides with the following features: (i) an N-connection to Fc (both Fc-NH-CO- and Fc-NH-CH<sub>2</sub>-); (ii) a relatively long spacer; (iii) a helical peptide or a peptide known to interact selectively with receptors over-expressed in cancer cells (<xref ref-type="bibr" rid="B39">Zhou et al., 2012</xref>; <xref ref-type="bibr" rid="B21">Ludwig et al., 2021</xref>). Since our experiments with human serum suggest that both peptide conformation and Fc itself may protect against enzyme degradation, we hypothesize that even a non-ordered and degradable peptide can be employed if it selectively guides the compound towards cancer cells. In this case, we may design a conjugate composed by Fc-long spacer-peptide-Fc, the second Fc unit having only the function of protecting the peptide from enzymatic cleavage.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>Cambridge Crystallographic Data Centre (CCDC) numbers 2497229-2497231 contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint CCDC and Fachinformationszentrum Karlsruhe Access Structures service <ext-link ext-link-type="uri" xlink:href="http://www.ccdc.cam.ac.uk/structures">www.ccdc.cam.ac.uk/structures</ext-link>
</p>
</sec>
<sec sec-type="ethics-statement" id="s7">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p>
</sec>
<sec sec-type="author-contributions" id="s8">
<title>Author contributions</title>
<p>AD: Writing &#x2013; original draft, Conceptualization, Methodology, Data curation, Investigation. BB: Methodology, Writing &#x2013; original draft, Investigation, Funding acquisition, Supervision, Conceptualization. AB: Writing &#x2013; original draft, Data curation, Methodology, Investigation. RC: Writing &#x2013; review and editing, Methodology, Investigation, Data curation. LL: Methodology, Investigation, Writing - review and editing, Data curation. M&#x160;: Writing - review and editing, Methodology, Data curation, Investigation. BC: Methodology, Data curation, Investigation, Writing - review and editing. FF: Supervision, Writing - review and editing, Writing - original draft, Conceptualization, Methodology, Investigation, Funding acquisition. MR: Writing - original draft, Investigation, Formal Analysis, Data curation, Methodology. SS: Writing &#x2013; original draft, Conceptualization, Methodology, Funding acquisition, Writing &#x2013; review and editing, Supervision.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The Bruker D8 Venture diffractometer at Department of Chemistry of the University of Padova was funded by the MUR-&#x201c;Dipartimenti di Eccellenza&#x201d; grantC2.&#x201d;</p>
</ack>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s11">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s13">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchbi.2026.1736812/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchbi.2026.1736812/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Presentation1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/60643/overview">Antonello Merlino</ext-link>, University of Naples Federico II, Italy</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/147435/overview">Andrea Ilari</ext-link>, National Research Council (CNR), Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1044440/overview">Luigi Vitagliano</ext-link>, National Research Council (CNR), Italy</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Di Stasi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schivo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mardirossian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scocchi</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Fragments of cathelicidins PMAP-36 and BMAP-27 and their D-enantiomers: effects of all D substitutions on structure, protease resistance and antimicrobial properties</article-title>. <source>Bioorg. Chem.</source> <volume>163</volume>, <fpage>108715</fpage>. <pub-id pub-id-type="doi">10.1016/.j.bioorg.2025.108715</pub-id>
<pub-id pub-id-type="pmid">40609280</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amatore</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lefrou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pfl&#xfc;ger</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>On-line compensation of ohmic drop in submicrosecond time resolved cyclic voltammetry at ultramicroelectrodes</article-title>. <source>J. Electroanal. Chem.</source> <volume>270</volume>, <fpage>43</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/0022-0728(89)85027-2</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Polborn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Metal complexes of biologically important ligands, CXIV ferrocenyl&#x2013;oxazolones as N and C donors in Pd(II), Pt(II) and Ir(III) complexes and ferrocenoyl&#x2013;dipeptides</article-title>. <source>J. Organomet. Chem.</source> <volume>579</volume>, <fpage>269</fpage>&#x2013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-328X(99)00009-1</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schiesari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cerveson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Facci</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Flat bis-ferrocenyl end-capped peptides: the influence of the molecular skeleton on redox properties</article-title>. <source>ChemElectroChem</source> <volume>8</volume>, <fpage>2693</fpage>&#x2013;<lpage>2700</lpage>. <pub-id pub-id-type="doi">10.1002/celc.202100597</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schiesari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Facci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cerveson</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Conformational analysis and through-chain charge propagation in ferrocenyl-conjugated homopeptides of 2,3-Diaminopropionic acid (dap) e202100966</article-title>. <source>Eur. J. Inorg. Chem.</source> <volume>2022</volume>, <fpage>e202100966</fpage>. <pub-id pub-id-type="doi">10.1002/ejic.202100966</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schiesari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Crisma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Formaggio</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Modulation of ferrocene&#x2013;ferrocene interactions by varying their reciprocal positions in <sub>L</sub>-Dap/Aib helical peptides</article-title>. <source>Inorganics</source> <volume>11</volume>, <fpage>482</fpage>. <pub-id pub-id-type="doi">10.3390/inorganics11120482</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boros</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>G&#xe1;sp&#xe1;ri</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Batta</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Accurate NMR determinations of proton-proton distances</article-title>. <source>Annu. Rep. NMR Spectrosc.</source> <volume>94</volume>, <fpage>1</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/bs.arnmr.2017.12.002</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhary</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Poonia</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The redox mechanism of ferrocene and its phytochemical and biochemical compounds in anticancer therapy: a mini review</article-title>. <source>Inorg. Chem. Commun.</source> <volume>134</volume>, <fpage>109044</fpage>. <pub-id pub-id-type="doi">10.1016/j.inoche.2021.109044</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crisma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moretto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Formaggio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Toniolo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Albericio</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Reactive intermediates in peptide synthesis: molecular and crystal structures of HOAt and HOOBt, and some ester and amide derivatives of HOBt, HOAt and HOOBt</article-title>. <source>Lett. Pept. Sci.</source> <volume>5</volume>, <fpage>247</fpage>&#x2013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1023/A:1008878209941</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tomoo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Akagi</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>1993</year>). <article-title>Structural characteristics of enantiomorphic DNA: crystal analysis of racemates of the d(CGCGCG) duplex</article-title>. <source>J. Am. Chem. Soc.</source> <volume>115</volume>, <fpage>10432</fpage>&#x2013;<lpage>10433</lpage>. <pub-id pub-id-type="doi">10.1021/ja00075a098</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolomanov</surname>
<given-names>O. V.</given-names>
</name>
<name>
<surname>Bourhis</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Gildea</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>J. A. K.</given-names>
</name>
<name>
<surname>Puschmann</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>
<italic>OLEX2</italic>: a complete structure solution, refinement and analysis program</article-title>. <source>J. Appl. Cryst.</source> <volume>42</volume>, <fpage>339</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1107/S0021889808042726</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marcuzzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moretto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Toniolo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Charge mapping in 3<sub>10</sub>-Helical peptide chains by oxidation of the Terminal Ferrocenyl Group</article-title>. <source>Org. Lett.</source> <volume>13</volume>, <fpage>1282</fpage>&#x2013;<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1021/ol102864s</pub-id>
<pub-id pub-id-type="pmid">21341757</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marcuzzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moretto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Crisma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Toniolo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>New bis-Ferrocenyl end-capped peptides: synthesis and charge transfer properties</article-title>. <source>Biopolymers</source> <volume>100</volume>, <fpage>14</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1002/bip.22197</pub-id>
<pub-id pub-id-type="pmid">23335164</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasser</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Metzler-Nolte</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Organometallic anticancer compounds</article-title>. <source>J. Med. Chem.</source> <volume>13</volume> (<issue>54</issue>), <fpage>3</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1021/jm100020w</pub-id>
<pub-id pub-id-type="pmid">21077686</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griesinger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Otting</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>W&#xfc;thrich</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>R. R.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Clean TOCSY for proton spin system identification in macromolecules</article-title>. <source>J. Am. Chem. Soc.</source> <volume>110</volume>, <fpage>7870</fpage>&#x2013;<lpage>7872</lpage>. <pub-id pub-id-type="doi">10.1021/ja00231a044</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harry</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Manton</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Pryce</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>O&#x2019;Donovan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Crown</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The synthesis, structural characterization and <italic>in vitro</italic> anti-cancer activity of novel 1-alkyl-10-N-para-(ferrocenyl) benzoyl dipeptide esters</article-title>. <source>J. Organomet. Chem.</source> <volume>757</volume>, <fpage>28</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.jorganchem.2014.01.031</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hummel</surname>
<given-names>R.-P.</given-names>
</name>
<name>
<surname>Toniolo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>Conformational transitions between Enantiomeric 3<sub>10</sub>-Helices</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>26</volume>, <fpage>1150</fpage>&#x2013;<lpage>1152</lpage>.</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Jenssen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aspmo</surname>
<given-names>S. I.</given-names>
</name>
</person-group> (<year>2008</year>). in <source>In peptide-based drug design: serum stability of peptides</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Otvos</surname>
<given-names>L.</given-names>
</name>
</person-group> (<publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana Press</publisher-name>), <fpage>177</fpage>&#x2013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1002/anie.198711501</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacic</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications</article-title>. <source>Med. Hypotheses</source> <volume>69</volume>, <fpage>510</fpage>&#x2013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2006.08.046</pub-id>
<pub-id pub-id-type="pmid">17383109</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacic</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Popp</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Ames</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Anti-cancer action of metal complexes: Electrontransfer and oxidative stress?</article-title> <source>Chem. Fac. Res. Publ.</source> <volume>602</volume>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://epublications.marquette.edu/chem_fac/602">https://epublications.marquette.edu/chem_fac/602</ext-link>.</comment>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludwig</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Tomassi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Di Maro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Di Leva</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Benge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reichart</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery <italic>via</italic> highly selective ligands to &#x3b1;v&#x3b2;3, &#x3b1;v&#x3b2;6, or &#x3b1;5&#x3b2;1 integrins</article-title>. <source>Biomaterials</source> <volume>271</volume>, <fpage>120754</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120754</pub-id>
<pub-id pub-id-type="pmid">33756215</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riganti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Costamagna</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bieganski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kopecka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kowalsky</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Two are better than one: a case study of the biferrocenyl-thymidine &#x201c;click&#x201d; conjugate biFcT as novel ferroptosis-inducing agent in lung cancer cells</article-title>. <source>Bioorg. Chem.</source> <volume>163</volume>, <fpage>108690</fpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2025.108690</pub-id>
<pub-id pub-id-type="pmid">40554208</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mooney</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Corry</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>O&#x2019;Sullivan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>P. T. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The synthesis, structural characterization and <italic>in vitro</italic> anti-cancer activity of novel N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl esters and novel N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters</article-title>. <source>J. Organomet. Chem.</source> <volume>694</volume>, <fpage>886</fpage>&#x2013;<lpage>894</lpage>. <pub-id pub-id-type="doi">10.1016/j.jorganchem.2008.09.064</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neuse</surname>
<given-names>E. W.</given-names>
</name>
<name>
<surname>Kanzawa</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Evaluation of the activity of some water-soluble ferrocene and ferricenium compounds against carcinoma of the lung by the human tumor clonogenic-assay</article-title>. <source>Appl. Organomet. Chem.</source> <volume>4</volume>, <fpage>19</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/aoc.590040105</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ornelas</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Application of ferrocene and its derivatives in cancer research</article-title>. <source>New J. Chem.</source> <volume>35</volume>, <fpage>1973</fpage>&#x2013;<lpage>1985</lpage>. <pub-id pub-id-type="doi">10.1039/C1NJ20172G</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ornelas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Astruc</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Ferrocene-Based drugs, delivery nanomaterials and fenton mechanism: state of the art, recent developments and prospects</article-title>. <source>Pharmaceutics</source> <volume>15</volume>, <fpage>2044</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics15082044</pub-id>
<pub-id pub-id-type="pmid">37631259</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The medicinal chemistry of ferrocene and its derivatives</article-title>. <source>Nat. Rev. Chem.</source> <volume>1</volume>, <fpage>0066</fpage>. <pub-id pub-id-type="doi">10.1038/s41570-017-0066</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peggion</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schivo</surname>
<given-names>A. ; M.</given-names>
</name>
<name>
<surname>Oancea</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Popovici</surname>
<given-names>L.-F.</given-names>
</name>
<name>
<surname>C&#x103;lin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mkrtchyan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Synthesis and biological activity of ultrashort antimicrobial peptides bearing a non-coded amino acid</article-title>. <source>J. Pept. Sci.</source> <volume>31</volume>, <fpage>e70021</fpage>. <pub-id pub-id-type="doi">10.1002/psc.70021</pub-id>
<pub-id pub-id-type="pmid">40230062</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rance</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>S&#xf8;rensen</surname>
<given-names>O. W.</given-names>
</name>
<name>
<surname>Bodenhausen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>W&#xfc;thrich</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Improved spectral resolution in COSY 1H NMR spectra of proteins <italic>via</italic> double quantum filtering</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>117</volume>, <fpage>479</fpage>&#x2013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1016/0006-291X(83)91225-1</pub-id>
<pub-id pub-id-type="pmid">6661238</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tomelleri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schiesari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Flat, ferrocenyl-conjugated peptides: a combined electrochemical and spectroscopic Study</article-title>. <source>ChemPlusChem</source> <volume>86</volume>, <fpage>723</fpage>&#x2013;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1002/cplu.202100072</pub-id>
<pub-id pub-id-type="pmid">33825347</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bisello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schiesari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tomelleri</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Helical <italic>versus</italic> flat bis-ferrocenyl end-capped peptides: the influence of the molecular skeleton on redox properties</article-title>. <source>Molecules</source> <volume>27</volume>, <fpage>6128</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27186128</pub-id>
<pub-id pub-id-type="pmid">36144860</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheldrick</surname>
<given-names>G. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>SHELXT &#x2013; integrated space-group and crystalstructure determination</article-title>. <source>Acta Cryst. A</source> <volume>71</volume>, <fpage>3</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1107/.S2053273314026370</pub-id>
<pub-id pub-id-type="pmid">25537383</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toniolo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peggion</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Crisma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Formaggio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shui</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Eggleston</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Structure determination of racemic trichogin A IV using centrosymmetric crystals</article-title>. <source>Nat. Struct. Mol. Biol.</source> <volume>1</volume>, <fpage>908</fpage>&#x2013;<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1038/nsb1294-908</pub-id>
<pub-id pub-id-type="pmid">7773780</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatachalam</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>1968</year>). <article-title>Stereochemical criteria for polypeptides and proteins. V. Conformation of a system of three linked peptide units</article-title>. <source>Biopolymers</source> <volume>6</volume>, <fpage>1425</fpage>&#x2013;<lpage>1436</lpage>. <pub-id pub-id-type="doi">10.1002/bip.1968.360061006</pub-id>
<pub-id pub-id-type="pmid">5685102</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Astruc</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Electron-reservoir applications of ferrocenes and other late transition-metal sandwich complexes: flow batteries, sensing, catalysis, and biomedicine</article-title>. <source>Coord. Chem. Rev.</source> <volume>524</volume>, <fpage>16300</fpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2024.216300</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>W&#xfc;thrich</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1991</year>). <source>NMR of proteins and nucleic acids</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>Wiley</publisher-name>.</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H. G.</given-names>
</name>
<name>
<surname>Annamadov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mokhir</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>4-Ferrocenylaniline-based ROS-responsive prodrugs with anticancer activity</article-title>. <source>J. Organomet. Chem.</source> <volume>964</volume>, <fpage>122305</fpage>. <pub-id pub-id-type="doi">10.1016/j.jorganchem.2022.122305</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zawadke</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>The structure of a centrosymmetric protein crystal</article-title>. <source>Prat. Struct. Funct. Genet.</source> <volume>16</volume>, <fpage>301</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1002/prot.340160308</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Syntheses and <italic>in vitro</italic> antitumor activities of ferrocene-conjugated arg-gly-asp peptides</article-title>. <source>J. Inorg. Biochem.</source> <volume>116</volume>, <fpage>19</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2012.06.014</pub-id>
<pub-id pub-id-type="pmid">23010325</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>